Adenocarcinoma of the lung classification
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Trusha Tank, M.D.[2]Shanshan Cen, M.D. [3] Sudarshana Datta, MD [4]
Overview
Adenocarcinoma of the lung may be classified according to WHO into many sub-types. Adenocarcinoma of the lung may be classified according to IASLC/ATS/ERS into pre-invasive lesions, atypical adenomatous hyperplasia, adenocarcinoma in situ, minimally invasive adenocarcinoma, invasive adenocarcinoma, and variants of invasive adenocarcinoma.
Classification
- Adenocarcinomas are highly heterogeneous tumors.
- Several major histological sub-types are currently recognized by the WHO and IASLC/ATS/ERS classification systems.[1][2][3]
- The IASLC/ATS/ERS lung adenocarcinoma histological classification system was proposed in 2011.[4]
- According to this new classification, tumor size ≤ 3 cm with pure lepidic pattern, but without lymphatic, vascular, and pleural invasion or tumor necrosis, was defined as adenocarcinoma in situ (AIS).
- If tumor size ≤ 3 cm with a lepidic predominant pattern and contained ≤ 5 mm stromal invasion, it was defined as minimally invasive adenocarcinoma (MIA).
- If tumor had > 5 mm stromal invasion, it was defined as an invasive adenocarcinoma.
- The WHO histological classification of adenocarcinoma is following:[5][6]
| WHO Classification of Lung Tumors | |
|---|---|
| Histological type | Subtype |
| Epithelial Tumors | |
| Adenocarcinoma |
|
References
- ↑ Van Schil, P. E.; Asamura, H; Rusch, V. W.; Mitsudomi, T; Tsuboi, M; Brambilla, E; Travis, W. D. (2012). “Surgical implications of the new IASLC/ATS/ERS adenocarcinoma classification”. European Respiratory Journal. 39 (2): 478–86. doi:10.1183/09031936.00027511. PMID 21828029.
- ↑ Travis, W. D.; Brambilla, E; Van Schil, P; Scagliotti, G. V.; Huber, R. M.; Sculier, J. P.; Vansteenkiste, J; Nicholson, A. G. (2011). “Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification”. European Respiratory Journal. 38 (2): 239–43. doi:10.1183/09031936.00026711. PMID 21804158.
- ↑ Vazquez, M; Carter, D; Brambilla, E; Gazdar, A; Noguchi, M; Travis, W. D.; Huang, Y; Zhang, L; Yip, R; Yankelevitz, D. F.; Henschke, C. I.; International Early Lung Cancer Action Program Investigators (2009). “Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: Histopathologic features and their prognostic implications”. Lung Cancer. 64 (2): 148–54. doi:10.1016/j.lungcan.2008.08.009. PMC 2849638. PMID 18951650.
- ↑ . doi:10.3978/j.issn.2072-1439.2014.09.13. Missing or empty
|title=(help) - ↑ Travis, William (2004). Pathology and genetics of tumours of the lung, pleura, thymus, and heart. Lyon: IARC Press. ISBN 9283224183.
- ↑ “www.jto.org”.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH